EE05419B1 - Asendatud oksasolidinoonid kombineeritud raviks - Google Patents

Asendatud oksasolidinoonid kombineeritud raviks

Info

Publication number
EE05419B1
EE05419B1 EEP200400020A EEP200400020A EE05419B1 EE 05419 B1 EE05419 B1 EE 05419B1 EE P200400020 A EEP200400020 A EE P200400020A EE P200400020 A EEP200400020 A EE P200400020A EE 05419 B1 EE05419 B1 EE 05419B1
Authority
EE
Estonia
Prior art keywords
combination therapy
substituted oxazolidinones
oxazolidinones
combinations
substituted
Prior art date
Application number
EEP200400020A
Other languages
English (en)
Inventor
Straub Alexander
Lampe Thomas
Pernerstorfer Josef
Perzborn Elisabeth
Pohlmann Jens
Rhrig Susanne
Schlemmer Karl-Heinz
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7688824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05419(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of EE200400020A publication Critical patent/EE200400020A/et
Publication of EE05419B1 publication Critical patent/EE05419B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200400020A 2001-06-20 2002-06-07 Asendatud oksasolidinoonid kombineeritud raviks EE05419B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129725A DE10129725A1 (de) 2001-06-20 2001-06-20 Kombinationstherapie substituierter Oxazolidinone
PCT/EP2002/006237 WO2003000256A1 (de) 2001-06-20 2002-06-07 Kombinationstherapie substituierter oxazolidinone

Publications (2)

Publication Number Publication Date
EE200400020A EE200400020A (et) 2004-04-15
EE05419B1 true EE05419B1 (et) 2011-06-15

Family

ID=7688824

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200400020A EE05419B1 (et) 2001-06-20 2002-06-07 Asendatud oksasolidinoonid kombineeritud raviks

Country Status (33)

Country Link
US (2) US7767702B2 (et)
EP (1) EP1411932B1 (et)
JP (1) JP4667744B2 (et)
KR (1) KR100904138B1 (et)
CN (1) CN100577162C (et)
AT (1) ATE457171T1 (et)
AU (1) AU2002312982B2 (et)
BG (1) BG66354B1 (et)
BR (1) BRPI0210941B8 (et)
CA (1) CA2451258C (et)
CO (1) CO5550434A2 (et)
CU (1) CU23366B7 (et)
CY (1) CY1110019T1 (et)
CZ (1) CZ303715B6 (et)
DE (2) DE10129725A1 (et)
DK (1) DK1411932T3 (et)
EC (1) ECSP034916A (et)
EE (1) EE05419B1 (et)
ES (1) ES2338997T3 (et)
HK (1) HK1068811A1 (et)
HR (1) HRP20040042B1 (et)
HU (1) HU230120B1 (et)
IL (2) IL159257A0 (et)
MX (1) MXPA03011519A (et)
NO (1) NO334821B1 (et)
NZ (1) NZ530223A (et)
PL (1) PL206803B1 (et)
PT (1) PT1411932E (et)
RU (1) RU2321407C9 (et)
SI (1) SI1411932T1 (et)
SK (1) SK287904B6 (et)
UA (1) UA82986C2 (et)
WO (1) WO2003000256A1 (et)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
JP2007525460A (ja) * 2003-04-25 2007-09-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ｃ−ｆｍｓキナーゼ阻害剤
WO2004101552A1 (en) * 2003-05-14 2004-11-25 Orchid Chemicals & Pharmaceuticals Ltd Oxazolidinone derivatives as antibacterial agents
DE10336716A1 (de) 2003-08-11 2005-03-10 Merck Patent Gmbh Verfahren zur Herstellung von N-Aryl-morpholinonen
US7687627B2 (en) * 2003-09-08 2010-03-30 Wockhardt Limited Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy
DE10342570A1 (de) * 2003-09-15 2005-04-14 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
EP1679067A4 (en) * 2003-09-19 2010-04-07 Kissei Pharmaceutical COMBINED MEDICINES
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
EP1893572B1 (en) 2004-06-18 2016-12-14 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005018690A1 (de) * 2005-04-22 2006-10-26 Bayer Healthcare Ag Imino-oxazolidine und ihre Verwendung
JP5214096B2 (ja) * 2005-06-17 2013-06-19 富士フイルムファインケミカルズ株式会社 新規なビピリジン誘導体
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047564A1 (de) * 2005-10-04 2007-05-31 Bayer Healthcare Ag Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
SG166126A1 (en) * 2005-10-04 2010-11-29 Bayer Schering Pharma Ag Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005052174A1 (de) 2005-11-02 2007-06-06 Bayer Healthcare Ag Phenylen-bis-oxazolidin-Derivate und ihre Verwendung
US7700590B2 (en) 2006-02-09 2010-04-20 University Of New Orleans Research And Technology Foundation, Inc. Antibacterial agents
DE102006007146A1 (de) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
TW200813017A (en) * 2006-05-05 2008-03-16 Millennium Pharm Inc Factor XA inhibitors
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
EP2141154A4 (en) * 2007-03-30 2011-06-01 Inst Med Molecular Design Inc OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11-HYDROXYSTEOID DEHYDROGENASE TYPE I
WO2008140220A1 (en) * 2007-05-09 2008-11-20 Legochem Bioscience Ltd. Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
KR101009594B1 (ko) * 2007-05-09 2011-01-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미딘을 가지는 ＦＸａ 저해제, 이의유도체, 제조방법 및 이를 함유하는 의약 조성물
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028320A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
ES2425183T3 (es) * 2007-08-14 2013-10-11 Concert Pharmaceuticals Inc. Derivados de oxazolidinonas sustituidas
EP2229173A1 (en) * 2007-12-11 2010-09-22 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones for the treatment and/or prophylaxis of heart failure
KR100898361B1 (ko) * 2008-07-03 2009-05-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물
ES2905760T3 (es) 2009-07-31 2022-04-12 Krka D D Novo Mesto Procedimientos para la cristalización del rivaroxabán
CN102050819B (zh) * 2009-11-10 2012-05-23 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
EP2513094B1 (en) * 2009-12-17 2015-12-16 Millennium Pharmaceuticals, Inc. Crystalline salts of a factor xa inhibitor
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
CN107021932A (zh) * 2010-06-29 2017-08-08 欧美嘉股份有限公司 制备5‑左旋‑氨甲基‑3‑芳基‑2‑恶唑烷酮类的方法
WO2012032533A2 (en) * 2010-09-07 2012-03-15 Symed Labs Limited Processes for the preparation of 4-{4-[5(s)-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl} morpholin-3-one
CN104693139B (zh) * 2011-01-07 2017-04-19 浙江九洲药业股份有限公司 一种合成利伐沙班中间体的新工艺
US9556163B2 (en) 2011-05-06 2017-01-31 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Process for the preparation of a rivaroxaban and intermediates formed in said process
EP2753619A2 (en) * 2011-09-08 2014-07-16 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
US9233989B2 (en) * 2011-10-11 2016-01-12 Council Of Scientific & Industrial Research Sila analogs of oxazolidinone derivatives and synthesis thereof
ES2647607T3 (es) 2012-12-21 2017-12-22 Farma Grs, D.O.O. Procedimiento para la preparación de rivaroxabán
CN105431429A (zh) * 2012-12-26 2016-03-23 Wanbury有限公司 取代的噁唑烷酮类的醛衍生物
CN103936763B (zh) * 2013-01-18 2017-10-31 中国科学院上海药物研究所 噁唑烷酮类化合物及其制备方法和用途
WO2015124995A1 (en) 2014-02-19 2015-08-27 Aurobindo Pharma Ltd Solid dosage forms of rivaroxaban
JP6389009B2 (ja) * 2014-10-30 2018-09-12 チェンデュ バイユ ファーマシューティカル カンパニー リミテッドＣｈｅｎｇｄｕ Ｂａｉｙｕ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． ギンコライドＢと第Ｘａ因子阻害剤とを含有する薬物組成物及びその製造方法と用途
CN104356124A (zh) * 2014-10-30 2015-02-18 广东东阳光药业有限公司 噁唑烷酮类化合物及其组合物和用途
CN104402876A (zh) * 2014-11-25 2015-03-11 沈阳药科大学 噁唑烷酮类化合物及其应用
CN104447729A (zh) * 2014-12-05 2015-03-25 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104447728B (zh) * 2014-12-05 2017-01-04 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104478866B (zh) * 2014-12-05 2017-07-07 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104497008B (zh) * 2014-12-09 2016-11-16 广东东阳光药业有限公司 取代噁唑烷酮类化合物及其使用方法和用途
LT3265126T (lt) 2015-03-03 2021-09-10 Saniona A/S Tesofensino ir metoprololio derinio kompozicija
US10828310B2 (en) 2018-02-02 2020-11-10 Bayer Pharma Aktiengesellschaft Reducing the risk of cardiovascular events
JP2021512960A (ja) * 2018-02-06 2021-05-20 シャンハイ ハイファ ファーマシューティカル カンパニー，リミティッド Ｂｅｔ阻害活性を有する化合物並びにその製造方法及び使用
US11608320B2 (en) 2020-02-02 2023-03-21 Kuwait University Oxazolidinone hydroxamic acid derivatives
CN111253383A (zh) * 2020-03-27 2020-06-09 南京国星生物技术研究院有限公司 一种利伐沙班的合成方法
CN112159402B (zh) * 2020-10-28 2022-04-05 南京法恩化学有限公司 一种利伐沙班的制备方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2811555A (en) * 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) * 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) * 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
HU190072B (en) * 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
ES533097A0 (es) 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
CA1317594C (en) 1987-10-21 1993-05-11 Chung-Ho Park Aminomethyloxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5654285A (en) * 1991-04-06 1997-08-05 Astra Pharmaceuticals Limited ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation
WO1993009103A1 (en) * 1991-11-01 1993-05-13 The Upjohn Company Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5349045A (en) * 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
DK0623615T3 (da) * 1993-05-01 1999-12-13 Merck Patent Gmbh Adhæsionsreceptor-antagonister
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
ES2163004T3 (es) * 1995-02-03 2002-01-16 Upjohn Co Feniloxazolidinona sustituida por un anillo heteroaromatico como agente antimicrobiano.
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
JP3651816B2 (ja) * 1995-07-03 2005-05-25 三共株式会社 動脈硬化症予防および治療剤
NO318765B1 (no) * 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
DE19524765A1 (de) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
KR100463772B1 (ko) 1995-09-01 2005-11-09 파마시아 앤드 업존 캄파니 엘엘씨 4내지8원헤테로사이클릭환에탄소-탄소결합을갖는페닐옥사졸리디논
ES2214546T3 (es) 1995-09-15 2004-09-16 PHARMACIA & UPJOHN COMPANY N-oxidos de aminoariloxazolidinona.
EP0874629B1 (en) 1995-12-21 2004-05-19 Bristol-Myers Squibb Pharma Company ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS
DE19601264A1 (de) 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
HRP970049A2 (en) * 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
KR100540618B1 (ko) * 1996-07-15 2006-01-12 상꾜 가부시키가이샤 의약 조성물
JPH1081632A (ja) * 1996-07-15 1998-03-31 Sankyo Co Ltd 医 薬
JP2001500875A (ja) * 1996-09-18 2001-01-23 メルク エンド カンパニー インコーポレーテッド 心臓血管系疾患関連の危険性を減らす併用治療法
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
SK156499A3 (en) 1997-05-30 2000-06-12 Upjohn Co Oxazolidinone antibacterial agents having a thiocarbonyl functionality
JP2002513424A (ja) 1997-07-11 2002-05-08 ファルマシア・アンド・アップジョン・カンパニー チアジアゾリルおよびオキサジアゾリルフェニルオキサゾリジノン抗菌剤
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
CA2303959A1 (en) 1997-11-12 1999-05-20 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions
US6083967A (en) 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
DE19802239A1 (de) 1998-01-22 1999-07-29 Bayer Ag Neue mit Bicyclen substituierte Oxazolidinone
EP1049682A1 (en) 1998-01-23 2000-11-08 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
KR20010034442A (ko) 1998-01-27 2001-04-25 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 치환된 옥소아자헤테로사이클릴 인자 Ｘａ 억제제
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
US20010029351A1 (en) * 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
SK283038B6 (sk) 1998-05-18 2003-02-04 Pharmacia And Upjohn Company Použitie oxazolidinónových antibakteriálnych látok, derivátov arginínu a farmaceutická kompozícia
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
EP1161279A1 (en) * 1999-03-11 2001-12-12 Du Pont Pharmaceuticals Company Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (es) 1999-12-14 2001-08-17 Upjohn Co Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
EP1242417A1 (en) 1999-12-21 2002-09-25 PHARMACIA & UPJOHN COMPANY Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CA2395948A1 (en) * 1999-12-28 2001-07-05 Ajinomoto Co., Inc. Crystal of aspartame derivative
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) * 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110754A1 (de) * 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de) * 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) * 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10152460A1 (de) 2001-10-24 2003-05-08 Bayer Ag Stents
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
SG166126A1 (en) 2005-10-04 2010-11-29 Bayer Schering Pharma Ag Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
DE102008028071A1 (de) * 2008-06-12 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure

Also Published As

Publication number Publication date
KR20040020058A (ko) 2004-03-06
PL368079A1 (en) 2005-03-21
SK15302003A3 (sk) 2004-07-07
NO334821B1 (no) 2014-06-10
NZ530223A (en) 2005-07-29
NO20035743L (no) 2004-02-17
BG108443A (en) 2005-03-31
CO5550434A2 (es) 2005-08-31
NO20035743D0 (no) 2003-12-19
DK1411932T3 (da) 2010-05-31
HU230120B1 (hu) 2015-08-28
MXPA03011519A (es) 2004-10-28
SI1411932T1 (sl) 2010-05-31
CA2451258A1 (en) 2003-01-03
EP1411932A1 (de) 2004-04-28
CU23366B7 (es) 2009-04-14
BG66354B1 (bg) 2013-09-30
US20100267685A1 (en) 2010-10-21
ATE457171T1 (de) 2010-02-15
CA2451258C (en) 2011-01-18
CN1523986A (zh) 2004-08-25
DE50214206D1 (de) 2010-03-25
JP4667744B2 (ja) 2011-04-13
RU2004101404A (ru) 2005-06-10
AU2002312982B2 (en) 2008-01-24
WO2003000256A9 (de) 2003-02-06
WO2003000256A1 (de) 2003-01-03
CZ20033451A3 (en) 2004-03-17
HUP0400240A3 (en) 2006-02-28
EE200400020A (et) 2004-04-15
HK1068811A1 (en) 2005-05-06
US20040242660A1 (en) 2004-12-02
BRPI0210941B8 (pt) 2021-05-25
PL206803B1 (pl) 2010-09-30
CZ303715B6 (cs) 2013-04-03
UA82986C2 (uk) 2008-06-10
IL159257A0 (en) 2004-06-01
HRP20040042B1 (hr) 2014-04-25
JP2004534083A (ja) 2004-11-11
DE10129725A1 (de) 2003-01-02
CN100577162C (zh) 2010-01-06
BR0210941A (pt) 2004-06-08
RU2321407C9 (ru) 2009-03-27
EP1411932B1 (de) 2010-02-10
ECSP034916A (es) 2004-02-26
IL159257A (en) 2010-02-17
ES2338997T3 (es) 2010-05-14
KR100904138B1 (ko) 2009-06-24
RU2321407C2 (ru) 2008-04-10
PT1411932E (pt) 2010-04-01
HUP0400240A2 (hu) 2004-08-30
US7767702B2 (en) 2010-08-03
BRPI0210941B1 (pt) 2015-09-15
HRP20040042A2 (en) 2005-04-30
SK287904B6 (sk) 2012-03-02
CY1110019T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
MY144616A (en) Substituted dihydroquinazolines
UA83233C2 (ru) Замещенный 2-аминотетралин для лечения депрессии
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
BR0209541A (pt) Uso das imidazotriazinonas 2-fenil-substituìdas
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
SE0004101D0 (sv) New use
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
SE0000303D0 (sv) Novel compounds
DE50203154D1 (de) Benzimidazolderivate zur behandlung von mit mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
UY27475A1 (es) Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
ATE406888T1 (de) Cyanoacrylat-zusammensetzungen für die therapeutische behandlungvon wunden, die eine revision erfordern
SE0202287D0 (sv) New compounds
UY26502A1 (es) Oxazolidinonas substituidas y su uso
LT2002105A (en) Novel use of siberian fir oil

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
GB1A Change in the ownership or in the address of the owner